-ADiN.jpg&w=347&h=240&crop-to-fit)
What were some of your professional highlights for 2023?
In 2023, my team and I achieved a significant milestone by obtaining both clinical and commercial validation for Onco-PDO. This involved garnering substantial clinical data and securing acceptance from esteemed clinical institutes to launch our service across global markets. This marks a pivotal moment for Invitrocue and solidifies our commitment to advancing precision medicine on a global scale.
How far in advance do you think about work strategies for the new year and how do you get started?
In preparing work strategies for the new year, my focus is on scaling Invitrocue globally in 2024. To achieve this, I've set two key milestones for the year ahead, and developed some concrete strategies / milestones to get there:
To ensure that Invitrocue gains recognition for its clinical intervention guidelines, my team and I will need to develop strategic positioning of our innovations in the healthcare landscape to emphasize their clinical impact and benefits.
By 2024, we aim to start expanding into major markets, including the United States. This means taking calculated steps to obtain recognition from the FDA, while navigating regulatory processes, establishing a strong presence in new territories, and building on the foundation we laid in Asia and Europe.
I also plan to participate in more medical conferences to showcase Invitrocue's advancements, learn from industry peers, and foster collaborations within the medical community to scale the company in the long-run.
Can you give us an overview of where you think your industry is headed in the coming year? What steps are you taking to ensure a smooth and favourable journey?
The healthcare industry is witnessing a transformative shift. The integration of AI into diagnostic tools is set to revolutionize cancer treatment with precise and personalized solutions.
We can expect the implementation of diagnostic tools that combine AI, cellular, and genetic insights for more accurate and efficient disease detection and treatment planning.
In addition, a crucial focus for biotech companies will be securing a balanced mix of dilutive and non-dilutive funding, ensuring financial flexibility to advance technologies like Onco-PDO on a global scale. This includes strategic planning, market assessments, regulatory considerations, and partnerships, which are key components of scaling nascent technologies globally.
(Related: How Rami Hajjar, CEO, Signify Southeast Asia is Heading in the Right Direction for 2024)
Back
